Rotavirus vaccines

Scandinavian Journal of Infectious Diseases

Volumn 40, Issue 9, 2008, Pages 691-695

  Vesikari, Timo ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; ROTAVIRUS VACCINE;

ACUTE GASTROENTERITIS; ANTIBODY RESPONSE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INTUSSUSCEPTION; LICENCE; POSTMARKETING SURVEILLANCE; REPEATED DRUG DOSE; REVIEW; ROTAVIRUS; SINGLE DRUG DOSE; VACCINATION; VIRUS INFECTION;

ANIMALS; CATTLE; CLINICAL TRIALS AS TOPIC; GASTROENTERITIS; HUMANS; INFANT; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; TREATMENT OUTCOME; VACCINATION; VACCINES, ATTENUATED;

EID: 50549086239     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540802040570     Document Type: Review

References (35)

1. Snyder, JD and Merson, MH. (1982) The magnitude of the global problem of acute diarrhoeal disease: A review of active surveillance data. Bull WHO, 60, pp. 605-613.
2. Parashar, UD, Hummelman, EG, Bresee, JS, Miller, MA and Glass, RT. (2003) Gloval illness and deaths caused by rotavirus disease in children. Emerg Infect Dis, 9, pp. 565-572.
3. The Pediatric ROTavisut European CommitTee (PROTECT) (2006) The paediatric burden of rotavirus disease in Europe. Epidemiol Infect, 134, pp. 908-916.
4. Soriano-Gabarro, M., Mrukowicz, J., Vesikari, T. and Verstraeten, T. (2006) Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J, 25, p. S7.
5. Vesikari, T., Isolauri, E., D'Hondt, E., Delem, A., Andre, FE and Zissis, G. (1984) Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet, 1, pp. 977-981.
6. Vesikari, T., Isolauri, E., Delem, A., D'Hondt, E., Andre, FE Beards, GM et al. (1985) Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. J Pediatr, 107, pp. 189-194.
7. Vesikari, T., Ruuska, T., Delem, A., Andre, FE, Beards, GM and Flewett, TH. (1991) Efficacy of 2 doses of RIT 4237 bovine rotavirus vaccine for prevention of rotavirus diarrhoea. Acta Paediatr Scand, 80, pp. 173-180.
8. Ruuska, T., Vesikari, T., Delem, A., Andre, FE, Beards, GM and Flewett, TH. (1990) Evaluation of RIT 4237 bovine rotavirus vaccine in newborn infants: Correlation of vaccine efficacy to season of birth in relation to rotavirus epidemic period. Scand J Infect Dis, 22, pp. 269-278.
9. Vesikari, T., Ruuska, T., Bogaerts, H., Delem, A. and Andre, F. (1985) Dose-response study of RIT 4237 oral rotavirus vaccine in breast-fed and formula-fed infants. Pediatr Infect Dis, 4, pp. 622-625.
10. Hanlon, P., Hanlon, L., Marsh, V., Byass, P., Shenton, F. Hassan-King, M. et al. (1987) Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet, 1, pp. 1342-1345.
11. Lanata, CF, Black, RE, del Aguila, R, Gil, A., Verastegui, H. Gerna, G. et al. (1989) Protection of Peruvian children against rotavirus diarrhoea of specific serotypes by 1, 2, or 3 doses of the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis, 159, pp. 425-429.
12. Linhares, AC, Lanata, CF, Hausdorff, WP, Gabbay, YB and Black, RE. (1999) Reappraisal of the Peruvian and Brazilian lower titre tetravalent rhesus-human reassortant rotavirus vaccine efficacy trials: Analysis by severity of diarrhoea. Pediatr Infect Dis J, 18, pp. 1001-1006.
13. Vesikari, T., Kapikian, AZ, Delem, A. and Zissis, G. (1986) A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. J Infect Dis, 153, pp. 832-839.
14. Vesikari, T., Rautanen, T., Varis, T., Beards, GM and Kapikian, AZ. (1990) Rhesus rotavirus candidate vaccine. Clinical trial in children vaccinated between 2 and 5 months of age. Am J Dis Child, 144, pp. 285-289.
15. Joensuu, J., Koskenniemi, E., Pang, X-L and Vesikari, T. (1997) Randomized placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet, 350, pp. 1205-1209.
16. Perez-Schael, I., Guntinas, MJ, Perez, M., Pagone, V., Rojas, AM Gonzalez, R. et al. (1997) Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med, 337, pp. 1181-1187.
17. Ward, RL and Bernstein, EI. (1995) Lack of correlation between serum rotavirus antibody titres and protection following vaccination with reassortant RRV vaccines. US Rotavirus Vaccine Efficacy Group. Vaccine, 13, pp. 1226-1232.
18. Vesikari, T., Clark, HF, Offit, PA, Dallas, MJ, DiStefano, DJ Goveia, MG et al. (2006) Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine, 24, pp. 4821-4829.
19. Ward, RL, Bernstein, DI, Smith, VE, Sander, DS, Shaw, A. Eiden, JJ et al. (2004) Rotavirus immunoglobulin A responses stimulated by each 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine. J Infect Dis, 189, pp. 2290-2293.
20. Bernstein, DI, Glass, RI, Rodgers, G., Davidson, BL, Sack, DA and for the US Rotavirus Vaccine Efficacy Group (1995) Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA, 273, pp. 1191-1196.
21. (1999) CDC. Intussusception among recipients of rotavirus vaccine-United States, 1998-1999. MMRV, 48, pp. 577-581.
22. Simonsen, L., Viboud, C., Elixhauser, A., Taylor, RJ and Kapikian, AZ. (2005) More on RotaShield and intussusception: The role of age at the time of vaccination. J Infect Dis, 192, p. S36.
23. Vesikari, T., Karvonen, AV, Majuri, J., Zeng, SQ, Pang, XL Kohberger, R. et al. (2006) Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. J Infect Dis, 194, pp. 370-376.
24. Bernstein, D., Smith, V., Sander, D., Pax, K., Schiff, G. and Ward, R. (1990) Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis, 162, pp. 10055-10062.
25. Vesikari, T., Matson, DO, Dennehy, P., van Damme, P., Santosham, M. Rodriguez, Z. et al. (2006) Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med, 354, pp. 23-33.
26. Vesikari, T., Itzler, R., Matson, DO, Santosham, M., Christie, CDC Coia, M. et al. (2007) Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across 3 regions (11 countries). Int J Infect Dis, 11, p. S29.
27. Prevention of rotavirus gastroenteritis in infants and children (2006) Recommendations of the Advisory Committee on Immunisation Practices (ACIP). MMWR, 55, pp. 1-13.
28. American Academy of Pediatrics, Committee on Infectious Diseases (2007) Prevention of Rotavirus Disease: Guidelines for Use of Rotavirus Vaccine. Pediatrics, 119, pp. 171-181.
29. Bernstein, DI, Smith, VE, Sherwood, JR, Schiff, GM, Sander, DS DeFeudis, D. et al. (1998) Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine, 16, pp. 381-387.
30. Bernstein, DI, Sack, DA, Rothstein, E., Reisinger, K., Smith, VE O'Sullivan, D. et al. (1999) Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: A randomized placebo-controlled trial. Lancet, 354, pp. 287-290.
31. Vesikari, T., Karvonen, A., Korhonen, T., Espo, M., Lebacq, E. Forster, J. et al. (2004) Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine, 22, pp. 2836-2842.
32. Salinas, B., Perez Schael, I, Linhares, AC, Ruiz Palacios, GM, Guerrero, ML Yarzabal, JP et al. (2005) Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine RIX4414: A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J, 24, pp. 807-816.
33. Ruiz-Palacios, GM, Perez-Schael, I., Velazquez, FR, Abate, H., Breuer, T. Clemens, SC et al. (2006) Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med, 354, pp. 11-22.
34. Vesikari, T., Karvonen, A., Prymula, R., Schuster, V., Tejedor, JC Cohen, R. et al. (2007) Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 y of life in European infants: Randomized, double-blind controlled study. Lancet, 370, pp. 1757-1763.
35. Vesikari, T., van Damme, P., Giaquinto, C., Gray, J., Mrukowicz, J. Dagan, R. et al. ESPID/ESPGHAN evidence-based recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol